Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

fuzzyjr

Rank: Vice President [?]

Points: 5268 [?]

Votes: 36 Score: 3.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA

in response to

Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA

BearDownAZ

posted on Mar 15, 2021 01:57PM

Thanks Bear - I was told in this sort of trial they would be able to observe quite quickly if the tumour(s) were shrinking ....I realize there's much more to look at than just that. Does the time line below seem quite long/2025? Is it possible there's a earlier point in the trial that could reveal something exciting enough for BP to step in , in your opinion?

TIA

Actual Study Start Date :	December 7, 2020
Estimated Primary Completion Date :	December 31, 2025
Estimated Study Completion Date :	December 31, 2025

3 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply